Forest Laboratories, Inc.

Company Description
Forest Laboratories, Inc. (Forest) develops, manufactures and sells branded forms of ethical drug products, which requires a physician's prescription. The Company's products include Namenda, a N-methyl-D-aspartate (NMDA) antagonist for the treatment of moderate to severe dementia of the Alzheimer's type; Bystolic, a beta-blocker for the treatment of hypertension; Linzess, a guanylate cyclase type-C receptor agonist for the once-daily treatment for men and women suffering from IBS-C or CIC; Tudorza, a long-acting antimuscarinic agent for the long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD) and Viibryd, a SSRI and a 5-HT1A receptor partial agonist for the treatment of adults with depressive disorder. In February 2014, it acquired Aptalis. In February 2014, Mayne Pharma Group Ltd completed the acquisition of the ESGIC, ESGIC PLUS, LORCET and LORCET PLUS brands and related assets from Forest Laboratories, Inc.